Leading Point Of Care Diagnostics Market participants are putting more effort into implementing cutting-edge technology like artificial intelligence to create effective point-of-care diagnostics. Lab-on-a-chip platforms, wearable technology, and breakthroughs in smartphone-based technologies have all led to significant improvements in POCT devices. Deep learning systems built on the cloud have prepared the way for coming upheavals.
New biosensors, microfluidics, and chip technology miniaturisation have advanced the design of novel diagnostic systems. One of the main forces behind POCT is lab-on-a-chip technology, notably in the detection of infectious diseases. Many bioassays, including microbiological culture, enzyme-linked immunosorbent assays (ELISA), and polymerase chain reactions (PCR), can now be employed at the point of care thanks to lab-on-a-chip technology. Manufacturers are concentrating on using ELISA for diagnosing infectious diseases. For instance, Trinity Biotech plc. received the CE Mark and registered the Captia SARS-CoV-2 IgG ELISA in January 2021.
Read More- https://cmi-latestreportorientedblogs.blogspot.com/2023/02/rising-prevalence-of-chronic-and.html
